Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.88
CRIS's Cash to Debt is ranked higher than
59% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CRIS: 1.88 )
CRIS' s 10-Year Cash to Debt Range
Min: 1.68   Max: No Debt
Current: 1.88

Equity to Asset 0.51
CRIS's Equity to Asset is ranked higher than
63% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRIS: 0.51 )
CRIS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.95
Current: 0.51

0.12
0.95
F-Score: 2
Z-Score: -13.23
M-Score: -1.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -165.70
CRIS's Operating margin (%) is ranked higher than
68% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. CRIS: -165.70 )
CRIS' s 10-Year Operating margin (%) Range
Min: -6639.83   Max: -35.24
Current: -165.7

-6639.83
-35.24
Net-margin (%) -183.87
CRIS's Net-margin (%) is ranked higher than
66% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. CRIS: -183.87 )
CRIS' s 10-Year Net-margin (%) Range
Min: -35140.52   Max: -27.72
Current: -183.87

-35140.52
-27.72
ROE (%) -42.81
CRIS's ROE (%) is ranked higher than
71% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. CRIS: -42.81 )
CRIS' s 10-Year ROE (%) Range
Min: -364.5   Max: -11.29
Current: -42.81

-364.5
-11.29
ROA (%) -22.89
CRIS's ROA (%) is ranked higher than
75% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CRIS: -22.89 )
CRIS' s 10-Year ROA (%) Range
Min: -331.19   Max: -10.23
Current: -22.89

-331.19
-10.23
ROC (Joel Greenblatt) (%) -2622.21
CRIS's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. CRIS: -2622.21 )
CRIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1898.02   Max: -66.78
Current: -2622.21

-1898.02
-66.78
Revenue Growth (%) -5.00
CRIS's Revenue Growth (%) is ranked higher than
74% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. CRIS: -5.00 )
CRIS' s 10-Year Revenue Growth (%) Range
Min: -40.5   Max: 72.9
Current: -5

-40.5
72.9
EBITDA Growth (%) 12.60
CRIS's EBITDA Growth (%) is ranked higher than
87% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. CRIS: 12.60 )
CRIS' s 10-Year EBITDA Growth (%) Range
Min: -49.4   Max: 25.5
Current: 12.6

-49.4
25.5
EPS Growth (%) 35.70
CRIS's EPS Growth (%) is ranked higher than
94% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CRIS: 35.70 )
CRIS' s 10-Year EPS Growth (%) Range
Min: -74.5   Max: 35.7
Current: 35.7

-74.5
35.7
» CRIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CRIS Guru Trades in Q4 2013

Jean-Marie Eveillard 17,889,009 sh (+2.65%)
» More
Q1 2014

CRIS Guru Trades in Q1 2014

Jean-Marie Eveillard 17,935,951 sh (+0.26%)
» More
Q2 2014

CRIS Guru Trades in Q2 2014

George Soros 44,000 sh (New)
Jim Simons 511,600 sh (New)
Jean-Marie Eveillard 19,468,451 sh (+8.54%)
» More
Q3 2014

CRIS Guru Trades in Q3 2014

Paul Tudor Jones 21,463 sh (New)
Jean-Marie Eveillard 19,568,451 sh (+0.51%)
Jim Simons Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Sold Out $1.4 - $1.92 $ 1.52-10%0
George Soros 2014-06-30 New Buy$1.63 - $2.97 $ 1.52-26%44000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.80
CRIS's P/B is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. CRIS: 3.80 )
CRIS' s 10-Year P/B Range
Min: 1.15   Max: 10.95
Current: 3.8

1.15
10.95
P/S 13.80
CRIS's P/S is ranked higher than
81% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. CRIS: 13.80 )
CRIS' s 10-Year P/S Range
Min: 2.69   Max: 382
Current: 13.8

2.69
382
EV-to-EBIT -6.76
CRIS's EV-to-EBIT is ranked higher than
58% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CRIS: -6.76 )
CRIS' s 10-Year EV-to-EBIT Range
Min: -49.9   Max: 1121.1
Current: -6.76

-49.9
1121.1
Current Ratio 5.81
CRIS's Current Ratio is ranked higher than
77% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CRIS: 5.81 )
CRIS' s 10-Year Current Ratio Range
Min: 2.89   Max: 25.89
Current: 5.81

2.89
25.89
Quick Ratio 5.81
CRIS's Quick Ratio is ranked higher than
78% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. CRIS: 5.81 )
CRIS' s 10-Year Quick Ratio Range
Min: 2.89   Max: 25.89
Current: 5.81

2.89
25.89

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.30
CRIS's Price/Net Cash is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. CRIS: 6.30 )
CRIS' s 10-Year Price/Net Cash Range
Min: 1.78   Max: 21.58
Current: 6.3

1.78
21.58
Price/Net Current Asset Value 5.80
CRIS's Price/Net Current Asset Value is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. CRIS: 5.80 )
CRIS' s 10-Year Price/Net Current Asset Value Range
Min: 1.78   Max: 20.78
Current: 5.8

1.78
20.78
Price/Tangible Book 5.10
CRIS's Price/Tangible Book is ranked higher than
82% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. CRIS: 5.10 )
CRIS' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 15.25
Current: 5.1

1.63
15.25
Price/Median PS Value 1.00
CRIS's Price/Median PS Value is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. CRIS: 1.00 )
CRIS' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 22.57
Current: 1

0.09
22.57
Earnings Yield (Greenblatt) -14.80
CRIS's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. CRIS: -14.80 )
CRIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -14.8   Max: 1.1
Current: -14.8

-14.8
1.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CUS.Germany
Curis, Inc., was organized as a Delaware corporation on February 14, 2000. It began its operations in July 2000 upon the completion of the merger of Creative BioMolecules, Inc., Ontogeny, Inc. and Reprogenesis, Inc. The Company is a drug discovery and development company that leverages its signaling pathway drug technologies to develop next generation targeted cancer therapies. The Company's advanced program is its Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly-owned member of the Roche Group. The drug candidate being developed under this program is Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor, which is also referred to as vismodegib, GDC-0449 and RG3616. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the U.S. National Cancer Institute. In addition to the ongoing clinical trials that Genentech and Roche are conducting, Genentech and the National Cancer Institute, entered into a collaborative relationship that allows the NCI to study GDC-0449 in additional potential cancer indications. The Company has in the U.S., 97 issued or allowed patents. The Company's competitors include large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms, that are developing cancer therapies in the same indications as it is. The Company is subject to government regulations.
» More Articles for CRIS

Headlines

Articles On GuruFocus.com
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 14 2013 
Weekly CFO Sells Highlight: USB, GNC, WWWW, GWRE, CRIS, CSL Apr 30 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 
Curis Inc. Reports Operating Results (10-Q) Aug 03 2010 
cooldecency99 note on CRIS May 01 2010 
Jean-Marie Eveillard Buys More Curis Inc. Aug 11 2009 
Curis Reports Second Quarter 2009 Financial Results and Provides Pipeline Update Jul 30 2009 
Curis Inc. Reports Operating Results (10-Q) May 06 2009 
Curis Reports Fourth Quarter and Year-End 2008 Financial Results Feb 10 2009 

More From Other Websites
Curis to Present at Upcoming Investor Conferences Nov 26 2014
Curis to Present at Upcoming Investor Conferences Nov 26 2014
Taseko and Curis announce completion of plan of arrangement Nov 20 2014
CURIS INC Financials Nov 18 2014
Curis receives final court approval for plan of arrangement with Taseko Nov 17 2014
10-Q for Curis, Inc. Nov 13 2014
Curis to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
Curis to Present at the Stifel 2014 Healthcare Conference Nov 12 2014
Curis Security Holders Approve Acquisition Of Curis By Taseko Nov 10 2014
CURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 10 2014
Curis Reports Third Quarter 2014 Financial Results and Pipeline Update Nov 10 2014
Curis misses Street 3Q forecasts Nov 10 2014
Curis misses Street 3Q forecasts Nov 10 2014
Q3 2014 Curis Inc Earnings Release - Before Market Open Nov 10 2014
Curis Reports Third Quarter 2014 Financial Results and Pipeline Update Nov 10 2014
Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014 Nov 03 2014
Q3 2014 Curis Inc Earnings Release-Tentative - Time Not Supplied Nov 03 2014
Curis to Release Third Quarter 2014 Financial Results and Hold Conference Call on November 10, 2014 Nov 03 2014
Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a... Oct 28 2014
Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a... Oct 28 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK